Author's reply to the letter to the editor: "Effects of dapagliflozin and empagliflozin on 6‑min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta‑analysis of randomized controlled trials involving 2624 patients"

Eur J Clin Pharmacol. 2024 Nov;80(11):1843-1844. doi: 10.1007/s00228-024-03733-2. Epub 2024 Jul 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Benzhydryl Compounds* / therapeutic use
  • Glucosides* / pharmacology
  • Glucosides* / therapeutic use
  • Heart Failure* / drug therapy
  • Humans
  • Randomized Controlled Trials as Topic*
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
  • Stroke Volume* / drug effects
  • Walk Test

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin
  • dapagliflozin
  • Sodium-Glucose Transporter 2 Inhibitors